drugset
drugset / Trial / NCT06367166

Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins

NCT06367166 ↗

Active not recruiting 100 enrolled Ryazan State Medical University
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).

Timeline

Start
2023-04-01
Primary completion
2026-04-01
Completion
2026-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Venarus® Unknown 1000 mg —

Indications

varicose disease